CMR e' as a novel diagnostic biomarker of Asymptomatic Left Ventricular Diastolic Dysfunction (ALVDD)
Author Block: N. Mcveigh1, D. T. Ryan1, F. Ryan2, M. Ferre2, J. Mccambridge2, M. Ledwidge2, K. Mcdonald2, J. Dodd1; 1Dublin 4/IE, 2Dublin/IE
Purpose: Evaluate a novel cardiac MRI biomarker of diastolic dysfunction, CMRe', in pre-clinical patients at risk of heart failure(HF).
Methods or Background: 236patients from the PARABLE trial(NCT04687111) underwent CMR. Mitral annular relaxation velocity(CMRe’) was measured at four mitral annular anchor points and compared with feature tracking analysis of radial, circumferential and longitudinal diastolic strain rate and velocity as the gold-standard. Comparison were made with a control group of 25 age/gender-matched subjects. Comparisons were made with independent t-test, diagnostic accuracy was performed with receiver operator curve analysis and predictors of diastolic dysfunction were analysed using logistic regression.
Results or Findings: LAVimax, LVEDVi, LVESVi and cardiac mass all demonstrated significant increases between patient and control groups (p<0.001 for all). Peak diastolic longitudinal velocity was the only significant feature tracking variable that differed between groups (p<0.001). LAVimax did not correlate with any measured feature tracking parameter when adjusted for clinical, left ventricle and left atrial parameters. In similar multivariate analysis, CMRe’ correlated with diastolic radial, circumferential and longitudinal strains rates, as well as radial and longitudinal diastolic velocity measurements (p<0.001). It also correlated with echo e’ (r=0.195,p=0.0069), LV mass (r=-.18,p=0.008), LAVimax (r=-.18,p=0.008) and BNP (r=-0.30,p<0.0001).
LAVimax and total CMR e’ both exhibited high accuracy as independent predictors of diastolic dysfunction (AUC:0.89, 0.76,p<0.001 for both).
Combined model (LAVImax and CMR e’ total) predicted diastolic dysfunction with an AUC = 0.99. LAVimax, CMR e’ and peak diastolic longitudinal velocity were independent predictors of diastolic dysfunction (p<0.001 for all), adjusted for clinical and standard CMR parameters.
Conclusion: CMRe' is a precise imaging biomarker for ALVDD. Integrating LAVimax and CMRe' holds promise in optimizing CMR methodologies for identifying patients at risk of diastolic dysfunction.
Limitations: Lack of BNP and Echo markers for the control group.
Funding for this study: This trial was supported by the Health Research Board of the Government of
Ireland, the European Commission Framework Programme 7, the Heartbeat
Trust CLG, and Novartis (the manufacturer of sacubitril/valsartan). Under the
terms of the grant from Novartis, the study was an investigator-led, Heartbeat
Trust–sponsored clinical trial.
Has your study been approved by an ethics committee? Yes
Ethics committee - additional information: SVUH Ethics Committee